arrow_back Back to App

Stopping Fake Petitions to Speed Up Generic Drug Approval

New rules aim to speed up access to cheaper generic and biosimilar drugs. The law will make it harder for pharmaceutical companies to file false petitions that delay the market entry of competitive, often cheaper alternatives. This means citizens may gain faster access to more affordable medications.
Key points
The Federal Trade Commission (FTC) gains tools to penalize companies filing baseless petitions intended to delay generic drug approval.
Companies filing such sham petitions can face significant fines, calculated based on revenues earned or a daily amount for each day of delay.
The goal is to increase competition in the pharmaceutical market, potentially leading to lower drug prices and wider availability for patients.
article Official text account_balance Process page
Placed on Calendar
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_1095
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2025-03-24
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Stop STALLING Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_1095.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-03-24.

What are the main provisions?

Key points include:

  • The Federal Trade Commission (FTC) gains tools to penalize companies filing baseless petitions intended to delay generic drug approval.
  • Companies filing such sham petitions can face significant fines, calculated based on revenues earned or a daily amount for each day of delay.
  • The goal is to increase competition in the pharmaceutical market, potentially leading to lower drug prices and wider availability for patients.
What is the specific legal status?

The current status is Placed on Calendar.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Courts and Law Economy